Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Top Cited Papers
- 20 June 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (18), 2992-2998
- https://doi.org/10.1200/jco.2007.15.9947
Abstract
Purpose To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). Patient...This publication has 19 references indexed in Scilit:
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Detection of Circulating Endothelial Cells: CD146-Based Magnetic Separation Enrichment or Flow Cytometric Assay?Journal of Clinical Oncology, 2007
- Angiogenesis and antiangiogenic therapy in hepatocellular carcinomaCancer Letters, 2006
- Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Opportunities for Targeted Therapies in Hepatocellular CarcinomaJournal of Clinical Oncology, 2005
- Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon ProgressionThe Oncologist, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Angiogenesis and hepatocellular carcinomaJournal of Hepatology, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Expression of vascular endothelial growth factor in human hepatocellular carcinomaHepatology, 1998